Nathan Singh

Using immunology, genomics and structural biology to engineer smarter cellular immunotherapies for cancer.

[Nathan Singh @NathanSinghLab]

Returning to Twitter (brielfy) to share publication of our article "BACH2 regulates T cell lineage state to enhance CAR T cell function" today in Nature Immunology! https://t.co/D92PSUkxLf
1 of 3 studies (!) (others led by @RoychoudhuriLab and Tuoqi Wu) published together that...

[Roychoudhuri Lab @RoychoudhuriLab]

The paper is part of three parallel submissions from @NathanSinghLab & Tuoqi Wu arriving at similar conclusions - that the dosage of BACH2 and the timing of its induction are key to enhancing #celltherapy for cancer. @Cambridge_Uni @CRUKCambridge

[Nathan Singh @NathanSinghLab]

Thanks also to Ben Youngblood for the hilarious News and Views that accompanies.

[Nathan Singh @NathanSinghLab]

Returning to Twitter (brielfy) to share publication of our article "BACH2 regulates T cell lineage state to enhance CAR T cell function" today in Nature Immunology! https://t.co/D92PSUkxLf
1 of 3 studies (!) (others led by @RoychoudhuriLab and Tuoqi Wu) published together that...

[Nathan Singh @NathanSinghLab]

identify the central role of BACH2 in T cell lineage decisions and function. A real pleasure working with the NI team and these great investigators! A great example complementary instead of competitive work strengthening the observation!

[Nathan Singh @NathanSinghLab]

Cell Therapy Keystone 2025 is coming! If you're interested in cell engineering, immunotherapy, cancer or autoimmunity (!) this meeting is for you! Join us in Banff for a fantastic symposium this March. Abstract deadline 12/9! @lab_rezvani

https://t.co/XTpXNAb2GG

[Nathan Singh @NathanSinghLab]

@HindRafei @YuSungHsu1 @lab_rezvani @ImmunologyGSBS Is there a way to triple like a picture? ❤️

[Nathan Singh @NathanSinghLab]

@EvanWeberPhD this is WILD!

[Nathan Singh @NathanSinghLab]

@HindRafei @YuSungHsu1 @ImmunologyGSBS @lab_rezvani @MDAndersonNews Woohoo! Go Kevin!

[Eric Holder @EricHolder]

There is no cavalry coming. No miracle solution. No saviors.

In the end, we, the American people-not any of our institutions-have to save our democracy by registering and voting in defense of our freedoms the next two months.

We are the cavalry. The responsibility is ours.

[Nathan Singh @NathanSinghLab]

Checkout our paired Perspective and Priority Brief in @CIR_AACR! Amazing collab with @carlhjune, @JoeFraietta and @GillSaar that we hope will help researchers, product developers and regulators advance gene edited T cell therapies.

https://t.co/rQaYYsDo8a

[Nathan Singh @NathanSinghLab]

Incredibly creative work highlighting the broad applications of T cell immunotherapy - congrats Jony and team!

[Jonathan Kipnis 🟦 @jonykipnis]

Excited to share a new work from @kipnislab by amazing Wenqing Gao (twitter-less) on developing engineered T cell therapy for CNS injury || https://t.co/0BAa3m7J5Q

[Nathan Singh @NathanSinghLab]

Looking for a small meeting with leaders in cell therapy discussing high impact translational research? Look no further! The UChicago Jonas Center Symposium is for you! Please get in touch if you're interested or, better yet, register and join us!

https://t.co/4VP2DPe5VO

[Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 @BLLPHD]

NEW - Regulatory Considerations for Genome-Edited T-cell Therapies, on navigating complexities in bringing new technologies to regulatory submissions, clinical trials. From @NathanSinghLab & colleagues @PennMedicine @CIR_AACR #geneediting #CRISPR https://t.co/wOLjjzIJ4Z

[Nathan Singh @NathanSinghLab]

Taken the day @JoeBiden announced his candidacy in 2019. A patriot that history will remember for doing the right, hard thing, over and over. We are lucky to have had him as President.

Now, let's kick it into gear for @VP @KamalaHQ and finish this!

[Elizabeth McKenna @ElizSMcKenna]

Now online in @CD_AACR: Rational Protein Engineering to Enhance MHC-independent T Cell Receptors - by Ju-Fang Chang, @NathanSinghLab, and colleagues https://t.co/0euvobb0BA @WUSTLmed

[Nathan Singh @NathanSinghLab]

Huge shout out to Twitter-less Ju-fang Chang, our structural biologist extraordinaire who drove this work from start to finish, and the amazing editorial team @CancerDiscovery. (4/4)

[Nathan Singh @NathanSinghLab]

Are all hybrid antigen receptors as easy to design as CARs? Definitely not! https://t.co/0w65w7slnJ (1/4)

[Nathan Singh @NathanSinghLab]

Using advanced modeling tools, we alleviated these conflicts to enhance receptor function across a variety of tumor models. A clear demonstration that design of synthetic immunotherapies requires consideration of de novo protein structures. (3/4)

[Nathan Singh @NathanSinghLab]

@EvanWeberPhD Wish Twitter had an "unlike" button.